3-(4-methylthiophenyl)-2-(4-pyridyl)-6,7-dihydro-[5H]-pyrrolo[1,2-a]imidazole | 122454-75-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(4-methylthiophenyl)-2-(4-pyridyl)-6,7-dihydro-[5H]-pyrrolo[1,2-a]imidazole
• 英文别名: 5h-Pyrrolo[1,2-a]imidazole,6,7-dihydro-3-[4-(methylthio)phenyl]-2-(4-pyridinyl)-；3-(4-methylsulfanylphenyl)-2-pyridin-4-yl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole
• CAS: 122454-75-5
• 化学式: C₁₈H₁₇N₃S
• 分子量: 307.419
• InChiKey: YOMQBGHQOXYELV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  56
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0306300A2

  公开（公告）日：1989-03-08

  Compounds comprising pyridyl and phenyl substituted pyrrolo[1,2-a]imidazole derivatives and pyridyl and phenyl substituted imidazo[1,2-a]pyridine derivatives, of formula wherein n = 0 or 1, and their use as 5-lipoxygenase pathway inhibitors.

  由吡啶基和苯基取代的吡咯并[1,2-a]咪唑衍生物和吡啶基和苯基取代的咪唑并[1,2-a]吡啶衍生物组成的化合物，其式为 其中 n = 0 或 1，以及它们作为 5-脂氧合酶途径抑制剂的用途。
• Pyrrolo[1,2-a]imidazole and imidazo[1,2-a]pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0364204A1

  公开（公告）日：1990-04-18

  Compounds of formula (I) in which one of R or R1 must be alkylsubstituted pyridyl, processes for their preparation, compositions containing them and their use as inhibitors of 5-lipoxygenase.

  式 (I) 的化合物 其中 R 或 R1 之一必须是烷基取代的吡啶基、其制备工艺、含有它们的组合物以及它们作为 5-脂氧合酶抑制剂的用途。
• Monokine activity interference
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0403251A2

  公开（公告）日：1990-12-19

  A method of treating a human afflicted with a T Cell Viral (TIV) infection, such as a human immunodeflciency virus (HIV) infection ,which comprises administering to such human an effective, monokine activity interfering amount of a monokine activity interfering agent.

  一种治疗 T 细胞病毒（TIV）感染（如人类免疫缺陷病毒（HIV）感染）患者的方法，包括向患者施用有效的、可干扰单核因子活性的单核因子活性干扰剂。
• Medicament for the inhibition of interleukin-1 or tumor necrosis factor production by monocytes and/or macrophages
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0411754A2

  公开（公告）日：1991-02-06

  A method of inhibiting the production of interleukin-1 by monocytes and/or macrophages in a human in need thereof which comprises administering to such a human an effective, interleukin-1 production inhibiting amount of a diaryl-substituted imidazole fused to a second heterocyclic ring containing a nitrogen bridgehead atom wherein said second ring may also contain sulfur, oxygen or an additional nitrogen atom, and may contain additional unsaturation. This invention relates to a method of inhibiting the production of Tumor Necrosis Factor (TNF) by monocytes or macrophages in a human in need thereof which comprises administering to such mammal an effective, TNF production inhibiting amount of a compound of Formula (I) as described herein. The compounds of Formula (II) are generally described as diaryl-substituted imidazole fused to a second heterocyclic ring containing a nitrogen bridgehead wherein said ring may also contain sulfur, oxygen, or an additional nitrogen atom, and may contain additional unsaturation.

  一种抑制有需要的人的单核细胞和/或巨噬细胞产生白细胞介素-1的方法，它包括向这种人施用有效的、抑制白细胞介素-1产生量的二芳基取代的咪唑与含有氮桥头原子的第二杂环融合，其中所述第二环也可含有硫、氧或另外的氮原子，并可含有另外的不饱和度。 本发明涉及一种抑制有需要的人体内的单核细胞或巨噬细胞产生肿瘤坏死因子（TNF）的方法，该方法包括向该哺乳动物施用有效的、可抑制 TNF 产生量的本文所述的式 (I) 化合物。式(II)化合物一般描述为二芳基取代的咪唑与含有氮桥头的第二个杂环融合，其中所述环还可含有硫、氧或额外的氮原子，并可含有额外的不饱和。
• US5145858A
  申请人：——

  公开号：US5145858A

  公开（公告）日：1992-09-08